|
Some unfortunate news: PTC Therapeutics has decided to discontinue the development of this program. According to representatives of the company, who spoke with FAST and ASF last week, the decision was not related to the investigational therapy but based on their company's strategic prioritization of other programs. Both they and we are committed to finding an outside partner to move this asset forward.
We know this news is disappointing. As Dr. Allyson Berent, FAST’s chief science officer, always says, drug development can feel like a series of chutes and ladders, and it would be understandable to see this move — coming after our community watched this program progress in the Angelman pipeline for over 8 years — as a slide down. But that’s why we do what we do at FAST, and in moments like these we don’t rest — we double down on our energy. We are going to advance as many promising therapeutic strategies as possible for Angelman syndrome, regardless of the obstacles, to find the BEST treatment options for our loved ones, for all ages and for all genotypes.
You can read the full press release from PTC Therapeutics here:
|